Billionaire David Einhorn’s 5 Stock Picks with Huge Upside Potential

4. Coya Therapeutics, Inc. (NASDAQ:COYA)

Greenlight Capital’s Stake Value: $1,797,377

Upside Potential as of December 1: 87.86%

Based in Houston, Texas, Coya Therapeutics, Inc. (NASDAQ:COYA) is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells. It is currently developing multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.

Howard Berman, Ph.D., Chief Executive Officer of Coya Therapeutics, Inc. (NASDAQ:COYA), made the following comments in Q3 2023 release:

“We are aiming for a busy end to 2023 and productive 2024 with numerous anticipated catalysts and milestones driving the value of the business. Of importance, we plan to release top-line double-blind, placebo-controlled Phase 2 data of LD IL-2 in AD, expected by summer 2024. We also intend to submit an IND application for a randomized double-blind placebo-controlled Phase 2 trial in ALS in 1H 2024. Further, we anticipate publishing multiple peer reviewed publications during this time related to blood biomarker findings in the prior LD IL-2/CTLA4Ig proof of concept clinical trial, as well as clinical data findings for LD IL-2 in AD”.